Researchers compared the demographics of patients in Oregon and Washington seeking medical aid in dying.
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Researchers followed up 10 years after the CALGB 49907 trial to see which treatment led to longer recurrence-free survival.
A new study surveyed 1,246 patients on whether they'd be willing to share electronic health records and biospecimens for research.
Researchers examined several studies of patients with Graves' Disease to see the prevalence of thyroid cancer in this population.
Researchers assessed patients with biliary tract cancer (BTC) who underwent ctDNA testing by means of a clinically available assay and analyzed samples using a 73-gene panel.
Researchers looked to see how a patient's monoclonal gammopathy of undetermined significance status affects their risk for multiple myeloma.
Researchers looked at the time between receiving a diagnosis and beginning chemotherapy to see if a delay in treatment impacted the overall survival in patients with breast cancer.
Many trials in the last decade that have led to FDA drug approvals didn't report on race and the ones that did were lacking in racial diversity.
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.